What is the current RNA Medicine market size?

The RNA Medicine market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the RNA Medicine market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the RNA Medicine market?

Key drivers include increasing demand for targeted therapies and advances in RNA technology.

What are the major challenges facing the RNA Medicine market?

Challenges include high development costs and regulatory hurdles.

Which regions are leading the RNA Medicine market?

North America and Europe are currently the leading regions.

Who are the top companies in the RNA Medicine market?

Top companies include Biogen and Pfizer, driving innovation and growth.

What are the future opportunities in the RNA Medicine market?

Future opportunities include expanding applications in oncology and rare diseases.

How is technology impacting the RNA Medicine market?

Advances in RNA technology are improving drug delivery and efficacy.

What is the current regulatory landscape for RNA Medicine?

The regulatory landscape is evolving, with increasing focus on safety and efficacy.

What is the future outlook for the RNA Medicine market?

The future outlook is promising, with expected growth and increasing adoption.

How Big Is the RNA Medicine Market? Size, Share & Forecast 2033

RNA Medicine by Application (Cancer, Diabetes, Tuberculosis, Cardiovascular Diseases, Others), by Types (siRNA, ASO, miRNA, Nucleic Acid Aptamers), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

RNA Medicine Market Size | CAGR 15.2 Forecast 2033

How Big Is the RNA Medicine Market? Size, Share & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

RNA Medicine Market Overview

The RNA Medicine market refers to the industry involved in the development and application of RNA-based therapies, which have gained significant relevance in recent years due to their potential in treating various diseases. As the RNA Medicine market size is estimated to be around $1.3 billion in 2025, the growth outlook and market forecast indicate a promising industry expansion. The scope of this market encompasses various segments, including RNA-based therapeutics, RNA-targeting therapies, and RNA-based diagnostics, with a focus on their applications in treating genetic disorders, cancer, and infectious diseases.

Loading chart…

The current RNA Medicine market is expected to grow at a CAGR of 15% during the forecast period, driven by macro drivers such as advancements in RNA technology, increasing investments in RNA-based research, and rising demand for personalized medicines. Key forces shaping the industry include technology shifts towards more efficient RNA delivery systems, evolving regulations supporting RNA-based innovation, and changing consumer behavior towards more targeted and effective treatments. The largest region in the RNA Medicine market is North America, while the fastest-growing region is Asia-Pacific, driven by increasing investments in RNA-based research and growing demand for innovative treatments.

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	37.22 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer (Pfizer); Roche (Roche); Sanofi-Aventis (Sanofi-Aventis); Abbott Laboratories (Abbott Laboratories); Arrowhead Pharmaceuticals; Benitec Biopharma; Calimmune Inc; Dicerna; Gradalis; Quark; RXi; Senesco; Silence Therapeutics; Silenseed; Tekmira; Alnylam Pharmaceuticals (Alnylam Pharmaceuticals)
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The RNA Medicine market is poised for significant growth, driven by advancements in gene editing technologies and increasing demand for targeted therapies. As the market continues to evolve, understanding the key dynamics driving growth, restraints, opportunities, and challenges is crucial for strategy leaders and business development heads.

Growth Drivers2 items

Advances in RNA interference and gene editing technologies are expanding the therapeutic applications of RNA Medicine, contributing to the growth forecast of the RNA Medicine market size.

Increasing investments in research and development, coupled with favorable regulatory environments, are fueling innovation and driving growth in the RNA Medicine market.

Restraints2 items

High development costs and the complexity of RNA Medicine manufacturing processes are significant restraints on the growth of the RNA Medicine market size, impacting the overall growth forecast.

Regulatory hurdles and the need for standardized guidelines for RNA Medicine approval processes are also hindering the pace of market expansion.

Opportunities2 items

The increasing prevalence of genetic disorders and cancer presents significant opportunities for RNA Medicine to address unmet medical needs, driving growth in the RNA Medicine market.

Collaborations between pharmaceutical companies, research institutions, and technology firms are expected to accelerate the development of RNA Medicine, further enhancing the growth forecast of the RNA Medicine market size.

Challenges2 items

Ensuring the scalability and cost-effectiveness of RNA Medicine production while maintaining quality and efficacy is a major challenge facing manufacturers and impacting the RNA Medicine market.

Addressing concerns related to the safety and efficacy of RNA Medicine, particularly long-term effects, is crucial for gaining widespread acceptance and realizing the full growth potential of the RNA Medicine market size.

Market Segmentation

Loading chart…

The RNA Medicine market can be segmented based on Application, which includes diagnostic and therapeutic applications. The diagnostic application segment holds a significant share of the RNA Medicine market, driven by the increasing demand for RNA-based diagnostics in the detection of various diseases. On the other hand, the therapeutic application segment is expected to grow at a rapid pace, driven by the rising adoption of RNA-based therapeutics in the treatment of genetic disorders and infectious diseases.

The RNA Medicine market can also be segmented based on Types, which includes small interfering RNA (siRNA), microRNA (miRNA), and messenger RNA (mRNA). The siRNA segment holds a significant share of the market, driven by its increasing adoption in the treatment of genetic disorders. The miRNA segment is expected to grow at a rapid pace, driven by its potential in the diagnosis and treatment of various diseases. The mRNA segment is also expected to grow significantly, driven by its increasing adoption in the development of vaccines and therapeutics. Understanding the RNA Medicine segmentation is crucial for market players to develop effective strategies and gain a competitive edge in the market.

RNA Medicine Segmentation Breakdown11 items

Application

Cancer

Diabetes

Tuberculosis

Cardiovascular Diseases

Others

Types

siRNA

ASO

miRNA

Nucleic Acid Aptamers

Regional Insights

Loading chart…

The RNA Medicine market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of RNA-based therapies, favorable policies, and significant investments in the healthcare sector.

Key drivers for each region include: for North America, demographics with an aging population, infrastructure with established healthcare systems, and ecosystem maturity with a strong presence of pharmaceutical companies. For Europe, drivers include regulatory support, research collaborations, and access to funding. In Asia Pacific, drivers include government initiatives, partnerships between companies, and a large patient population. Latin America is driven by increasing healthcare expenditure, growing awareness of RNA-based therapies, and expanding distribution networks. The Middle East & Africa region is driven by economic growth, improving healthcare infrastructure, and rising demand for innovative treatments.

The regional forecast indicates that Asia Pacific will experience the highest growth rate, driven by emerging markets such as China and India. The RNA Medicine market is expected to witness significant growth in the coming years, with the global market projected to reach a substantial value by 2025. Understanding the regional dynamics and key drivers is crucial for companies to develop effective strategies and capitalize on the growing demand for RNA-based therapies.

Competitive Landscape

The RNA Medicine market is moderately consolidated, with a mix of global players and local companies competing on factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The RNA Medicine competitive landscape is driven by key competitive levers, including pricing strategies and product innovation, with global players focusing on expanding their product portfolios and local companies concentrating on regional expansion and partnerships. The market structure is characterized by high competition, with companies employing various strategies to differentiate themselves and gain market share.

Companies in the RNA Medicine market employ common strategies such as M&A, partnerships, product launches, expansion, R&D, and localization to stay competitive. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To differentiate themselves, companies focus on technology, service model, channel strength, customization, and cost advantages. The following companies have adopted specific strategic focuses:

Pfizer: regional expansion

Roche: innovation pipeline

Sanofi-Aventis: premium pricing

Alnylam Pharmaceuticals: vertical integration

Arrowhead Pharmaceuticals: local manufacturing

Benitec Biopharma: OEM tie-ups

Key RNA Medicine Companies16 items

Pfizer (Pfizer)

Roche (Roche)

Sanofi-Aventis (Sanofi-Aventis)

Abbott Laboratories (Abbott Laboratories)

Arrowhead Pharmaceuticals

Benitec Biopharma

Calimmune Inc

Dicerna

Gradalis

Quark

RXi

Senesco

Silence Therapeutics

Silenseed

Tekmira

Alnylam Pharmaceuticals (Alnylam Pharmaceuticals)

Market Ecosystem

The RNA Medicine ecosystem spans the entire value chain, from upstream technology providers and suppliers to midstream integrators and downstream channels and end users. This complex network creates and captures value through the development, manufacturing, and distribution of RNA-based therapies. The ecosystem boundaries are defined by the interactions between these various participants, influencing how value is created and captured.

Raw material suppliers — provide essential components

Technology providers — develop RNA-based technologies

OEMs/manufacturers — produce RNA-based therapies

System integrators/EPCs — integrate therapies into treatment regimens

Distributors/channel partners — distribute therapies to end users

Regulators/standards bodies — establish guidelines and approvals

End users/buyers — receive RNA-based therapies

In the RNA Medicine ecosystem, control points are primarily held by regulators and standards bodies, as they influence adoption through approvals and guidelines. Dependency risks arise from input constraints, such as access to raw materials, and standards, which can impact the development and distribution of RNA-based therapies. Switching costs and partnerships are also critical, as they can affect the interoperability of different therapies and treatment regimens. Furthermore, the ecosystem differs by region, with varying regulatory frameworks and market conditions influencing the development and adoption of RNA Medicine. A thorough value chain analysis is essential to understanding these complexities and navigating the RNA Medicine ecosystem.

Recent Industry Insights

The RNA Medicine industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between pharmaceutical companies and biotechnology firms, have accelerated innovation in the field. Notable mergers and acquisitions, like the acquisition of small biotech companies by large pharmaceutical players, have also contributed to the growth of the industry. Furthermore, the launch of new products and technologies, including RNA-based therapeutics and diagnostics, has expanded the scope of RNA medicine.

Additionally, regulatory changes, such as the updated guidelines for RNA-based product development, have provided a clearer framework for companies operating in the space. A shift in consumer trends towards personalized medicine has also driven demand for RNA-based treatments. Moreover, funding rounds and expansions, including investments in RNA-based startups, have provided the necessary capital to support research and development in the field, ultimately shaping the future of the RNA Medicine industry.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the RNA Medicine market outlook, highlighting its attractiveness, competitive intensity, and long-term prospects. The RNA Medicine market outlook is promising, driven by innovative therapies and growing demand for targeted treatments. Competitive intensity is moderate, with key players investing heavily in research and development.

The innovation landscape is rapidly evolving, with advancements in RNA technologies and increasing focus on personalized medicine. However, the demand–supply balance poses a challenge, with potential risks including regulatory hurdles, high development costs, and intellectual property disputes. Key risk factors, such as supply chain disruptions and pricing pressures, must be carefully managed to ensure sustainable growth in the RNA Medicine market.

11 items

1. Executive Summary

2. RNA Medicine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global RNA Medicine Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global RNA Medicine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Cancer

6.1.2. Diabetes

6.1.3. Tuberculosis

6.1.4. Cardiovascular Diseases

6.1.5. Others

6.2. Global RNA Medicine Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. siRNA

6.2.2. ASO

6.2.3. miRNA

6.2.4. Nucleic Acid Aptamers

6.3. Global RNA Medicine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global RNA Medicine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global RNA Medicine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global RNA Medicine Market Competition by Key Manufacturers

8.1. Global RNA Medicine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global RNA Medicine: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Pfizer (Pfizer)

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Roche (Roche)

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Sanofi-Aventis (Sanofi-Aventis)

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Abbott Laboratories (Abbott Laboratories)

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Arrowhead Pharmaceuticals

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Benitec Biopharma

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Calimmune Inc

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Dicerna

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Gradalis

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Quark

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. RXi

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Senesco

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Silence Therapeutics

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Silenseed

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Tekmira

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Alnylam Pharmaceuticals (Alnylam Pharmaceuticals)

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global RNA Medicine Market

Figure 4: Global RNA Medicine Market: Drivers

Figure 5: Global RNA Medicine Market: Challenges

Figure 6: Global RNA Medicine Market: Trends

Figure 7: Global RNA Medicine Market: Opportunity

Figure 8: Global RNA Medicine Market: Restraint

Figure 9: Global RNA Medicine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global RNA Medicine Market Value (USD Million) By Region

Figure 15: Global RNA Medicine Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global RNA Medicine Market Value (USD Million) By Region

Figure 23: Global RNA Medicine Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global RNA Medicine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global RNA Medicine Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global RNA Medicine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global RNA Medicine Market Value (USD Million) By Region

Table 10: Global RNA Medicine Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global RNA Medicine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global RNA Medicine Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global RNA Medicine Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Pfizer (Pfizer) Basic Information And Sales Area

Table 31: Pfizer (Pfizer). Products Portfolio

Table 32: Roche (Roche) Basic Information And Sales Area

Table 33: Roche (Roche). Products Portfolio

Table 34: Sanofi-Aventis (Sanofi-Aventis) Basic Information And Sales Area

Table 35: Sanofi-Aventis (Sanofi-Aventis). Products Portfolio

Table 36: Abbott Laboratories (Abbott Laboratories) Basic Information And Sales Area

Table 37: Abbott Laboratories (Abbott Laboratories). Products Portfolio

Table 38: Arrowhead Pharmaceuticals Basic Information And Sales Area

Table 39: Arrowhead Pharmaceuticals. Products Portfolio

Table 40: Benitec Biopharma Basic Information And Sales Area

Table 41: Benitec Biopharma. Products Portfolio

Table 42: Calimmune Inc Basic Information And Sales Area

Table 43: Calimmune Inc. Products Portfolio

Table 44: Dicerna Basic Information And Sales Area

Table 45: Dicerna. Products Portfolio

Table 46: Gradalis Basic Information And Sales Area

Table 47: Gradalis. Products Portfolio

Table 48: Quark Basic Information And Sales Area

Table 49: Quark. Products Portfolio

Table 50: RXi Basic Information And Sales Area

Table 51: RXi. Products Portfolio

Table 52: Senesco Basic Information And Sales Area

Table 53: Senesco. Products Portfolio

Table 54: Silence Therapeutics Basic Information And Sales Area

Table 55: Silence Therapeutics. Products Portfolio

Table 56: Silenseed Basic Information And Sales Area

Table 57: Silenseed. Products Portfolio

Table 58: Tekmira Basic Information And Sales Area

Table 59: Tekmira. Products Portfolio

Table 60: Alnylam Pharmaceuticals (Alnylam Pharmaceuticals) Basic Information And Sales Area

Table 61: Alnylam Pharmaceuticals (Alnylam Pharmaceuticals). Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Types

Table 65: Global Market Share (%) By Types (2032)

Table 66: Global RNA Medicine Market Value (USD Million) By Region

Table 67: Global RNA Medicine Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: North America Market Value (USD Million) (2025-2032) By Types

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Types

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Types

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

RNA Medicine Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	37.22 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer (Pfizer); Roche (Roche); Sanofi-Aventis (Sanofi-Aventis); Abbott Laboratories (Abbott Laboratories); Arrowhead Pharmaceuticals; Benitec Biopharma; Calimmune Inc; Dicerna; Gradalis; Quark; RXi; Senesco; Silence Therapeutics; Silenseed; Tekmira; Alnylam Pharmaceuticals (Alnylam Pharmaceuticals)
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options